Evotec Achieves Clinical Development Milestone from Bayer
News Aug 04, 2016
This milestone was achieved under the strategic alliance between Evotec and Bayer entered in October 2012. The goal of the collaboration is to develop three clinical candidates within the five-year alliance. Both parties contribute innovative drug targets and high-quality technology infrastructures and share the responsibility for early research and pre-clinical characterisation of potential clinical candidates in the disease area of endometriosis.
Bayer will be responsible for subsequent clinical development and commercialisation while Evotec is eligible for clinical and sales milestones as well as royalties on net sales depending on the successful development and approval of a potential drug candidate.
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: “We are very pleased to report this exciting progress in our endometriosis collaboration with Bayer. The progression of this programme into clinical development is a significant achievement for the alliance. We look forward to continued success within the alliance as we strive to deliver new therapeutics for the treatment of this disease with significant unmet medical need.”
Compound Selectively Kills Liver Cancer Stem CellsNews
Acyclic retinoid, an artificial compound derived from vitamin A, has been found to prevent the recurrence of hepatocellular carcinoma (HCC), the most common form of liver cancer.READ MORE
170 Potential Lung Cancer Drug Targets Identified Using Unique Cellular LibraryNews
After testing more than 200,000 chemical compounds, UT Southwestern’s Simmons Cancer Center researchers have identified 170 chemicals that are potential candidates for development into drug therapies for lung cancer.READ MORE
Primary Pancreatic Organoid Tumor Models for High-Throughput Phenotypic Drug ScreeningNews
A multidisciplinary team of scientists share recent advancements in innovative in-vitro cancer biology methods for screening drug-like molecules in cancer tissue relevant models in a new report published online ahead-of-print at SLAS Discovery.READ MORE